TreC_Metha: A Digital Application to Enhance Patient Agency, Therapy Compliance and Quality of Life in Metastatic Breast Cancer Patients
The prognosis for Hormonal Receptor positive-HER2-negative (HR+ HER2-negative) metastatic breast cancer (mBC) has significantly improved by advances in hormone therapies, targeted drugs, and antibody–drug conjugates (ADCs). Nevertheless, maintaining quality of life (QoL), managing symptoms, and redu...
Saved in:
| Main Authors: | Antonella Ferro, Maria Chiara Pavesi, Lucia Pederiva, Claudio Eccher |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/32/6/299 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
INTRAPLEURAL IMMUNOTHERAPY FOR METASTATIC PLEURISIES IN PATIENTS WITH BREAST CANCER
by: K. S. Titov, et al.
Published: (2014-09-01) -
Features of Breast Cancer Progression after Comprehensive Treatment, Prognosis of Metastatic Spread
by: Yu. Chuprovska, et al.
Published: (2025-06-01) -
Comprehensive mapping elucidates high risk genotypes in primary metastatic breast cancer
by: Tobias Berg, et al.
Published: (2025-05-01) -
Stroke associated with microvascular tumoral infiltration in a patient with metastatic breast cancer
by: Joshua Mangerel, MD, et al.
Published: (2025-03-01) -
Assessing equity of care across metastatic breast cancer treatment junctures: a multi-site retrospective cohort study
by: Carolyn Brown, et al.
Published: (2025-05-01)